These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12617924)

  • 1. Amphipathic 3-phenyl-7-propylbenzisoxazoles; human pPaR gamma, delta and alpha agonists.
    Adams AD; Yuen W; Hu Z; Santini C; Jones AB; MacNaul KL; Berger JP; Doebber TW; Moller DE
    Bioorg Med Chem Lett; 2003 Mar; 13(5):931-5. PubMed ID: 12617924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents.
    Desai RC; Han W; Metzger EJ; Bergman JP; Gratale DF; MacNaul KL; Berger JP; Doebber TW; Leung K; Moller DE; Heck JV; Sahoo SP
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2795-8. PubMed ID: 12873517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural requirements and cell-type specificity for ligand activation of peroxisome proliferator-activated receptors.
    Johnson TE; Holloway MK; Vogel R; Rutledge SJ; Perkins JJ; Rodan GA; Schmidt A
    J Steroid Biochem Mol Biol; 1997; 63(1-3):1-8. PubMed ID: 9449199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
    Sauerberg P; Pettersson I; Jeppesen L; Bury PS; Mogensen JP; Wassermann K; Brand CL; Sturis J; Wöldike HF; Fleckner J; Andersen AS; Mortensen SB; Svensson LA; Rasmussen HB; Lehmann SV; Polivka Z; Sindelar K; Panajotova V; Ynddal L; Wulff EM
    J Med Chem; 2002 Feb; 45(4):789-804. PubMed ID: 11831892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
    Etgen GJ; Oldham BA; Johnson WT; Broderick CL; Montrose CR; Brozinick JT; Misener EA; Bean JS; Bensch WR; Brooks DA; Shuker AJ; Rito CJ; McCarthy JR; Ardecky RJ; Tyhonas JS; Dana SL; Bilakovics JM; Paterniti JR; Ogilvie KM; Liu S; Kauffman RF
    Diabetes; 2002 Apr; 51(4):1083-7. PubMed ID: 11916929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.
    Berger J; Bailey P; Biswas C; Cullinan CA; Doebber TW; Hayes NS; Saperstein R; Smith RG; Leibowitz MD
    Endocrinology; 1996 Oct; 137(10):4189-95. PubMed ID: 8828476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential.
    Dey D; Medicherla S; Neogi P; Gowri M; Cheng J; Gross C; Sharma SD; Reaven GM; Nag B
    Metabolism; 2003 Aug; 52(8):1012-8. PubMed ID: 12898466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for peroxisome proliferator-activated receptor (PPAR)alpha-independent peroxisome proliferation: effects of PPARgamma/delta-specific agonists in PPARalpha-null mice.
    DeLuca JG; Doebber TW; Kelly LJ; Kemp RK; Molon-Noblot S; Sahoo SP; Ventre J; Wu MS; Peters JM; Gonzalez FJ; Moller DE
    Mol Pharmacol; 2000 Sep; 58(3):470-6. PubMed ID: 10953038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists.
    Koyama H; Boueres JK; Han W; Metzger EJ; Bergman JP; Gratale DF; Miller DJ; Tolman RL; MacNaul KL; Berger JP; Doebber TW; Leung K; Moller DE; Heck JV; Sahoo SP
    Bioorg Med Chem Lett; 2003 May; 13(10):1801-4. PubMed ID: 12729668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice.
    Yajima K; Hirose H; Fujita H; Seto Y; Fujita H; Ukeda K; Miyashita K; Kawai T; Yamamoto Y; Ogawa T; Yamada T; Saruta T
    Am J Physiol Endocrinol Metab; 2003 May; 284(5):E966-71. PubMed ID: 12676649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.
    Zinman B
    Diabetes Obes Metab; 2001 Aug; 3 Suppl 1():S34-43. PubMed ID: 11685828
    [No Abstract]   [Full Text] [Related]  

  • 12. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.
    Singh Ahuja H; Liu S; Crombie DL; Boehm M; Leibowitz MD; Heyman RA; Depre C; Nagy L; Tontonoz P; Davies PJ
    Mol Pharmacol; 2001 Apr; 59(4):765-73. PubMed ID: 11259621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity.
    Vikramadithyan RK; Chakrabarti R; Misra P; Premkumar M; Kumar SK; Rao CS; Ghosh A; Reddy KN; Uma C; Rajagopalan R
    Metabolism; 2000 Nov; 49(11):1417-23. PubMed ID: 11092504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities.
    Doebber TW; Kelly LJ; Zhou G; Meurer R; Biswas C; Li Y; Wu MS; Ippolito MC; Chao YS; Wang PR; Wright SD; Moller DE; Berger JP
    Biochem Biophys Res Commun; 2004 May; 318(2):323-8. PubMed ID: 15120604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic.
    Misra P; Chakrabarti R; Vikramadithyan RK; Bolusu G; Juluri S; Hiriyan J; Gershome C; Rajjak A; Kashireddy P; Yu S; Surapureddi S; Qi C; Zhu YJ; Rao MS; Reddy JK; Ramanujam R
    J Pharmacol Exp Ther; 2003 Aug; 306(2):763-71. PubMed ID: 12730351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation.
    Nugent C; Prins JB; Whitehead JP; Savage D; Wentworth JM; Chatterjee VK; O'Rahilly S
    Mol Endocrinol; 2001 Oct; 15(10):1729-38. PubMed ID: 11579205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
    Shibata T; Matsui K; Nagao K; Shinkai H; Yonemori F; Wakitani K
    Eur J Pharmacol; 1999 Jan; 364(2-3):211-9. PubMed ID: 9932726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR gamma-dependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNF alpha secretion is not mediated by PTEN regulation.
    Hong G; Davis B; Khatoon N; Baker SF; Brown J
    Biochem Biophys Res Commun; 2003 Apr; 303(3):782-7. PubMed ID: 12670479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic scavenger receptor class B, type I is stimulated by peroxisome proliferator-activated receptor gamma and hepatocyte nuclear factor 4alpha.
    Malerød L; Sporstøl M; Juvet LK; Mousavi A; Gjøen T; Berg T
    Biochem Biophys Res Commun; 2003 Jun; 305(3):557-65. PubMed ID: 12763030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.